Octagon Capital Advisors LP Ambrx Biopharma Inc. Transaction History

Octagon Capital Advisors LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$2.53 - $4.35 $67,298 - $115,709	-26,600 Reduced 17.8%	122,800 $325,000
Q1 2022 May 16, 2022	SELL	$4.07 - $9.0 $762,994 - $1.69 Million	-187,468 Reduced 55.65%	149,400 $616,000
Q4 2021 Feb 14, 2022	SELL	$8.11 - $13.91 $106,500 - $182,666	-13,132 Reduced 3.75%	336,868 $3.04 Million
Q3 2021 Nov 15, 2021	SELL	$13.31 - $22.53 $1.33 Million - $2.25 Million	-100,000 Reduced 22.22%	350,000 $4.73 Million
Q2 2021 Aug 16, 2021	BUY	$15.95 - $19.6 $7.18 Million - $8.82 Million	450,000 New	450,000 $8.82 Million

31.2K

Ticker AMAM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,618,400
Market Cap $1.08B
Description
Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gas...

Get notified when there are updates to the investment portfolio of Octagon Capital Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Octagon Capital Advisors LP with notifications on news.